Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation

Journal of Clinical Oncology

Volumn 19, Issue 17, 2001, Pages 3758-3765

  Anscher, M S ^a   Marks, L B ^a   Shafman, T D ^a   Clough, R ^a   Huang, H ^a   Tisch, A ^a   Munley, M ^a   Herndon II, J E ^a   Garst, J ^a   Crawford, J ^a   Jirtle, R L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIATION INJURY; TREATMENT PLANNING;

EID: 0035449431     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.17.3758     Document Type: Article

References (76)

1. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat cell carcinoma of the lung
2. Impact of tumor control on survival in carcinoma of the lung treated with irradiation
3. The relationship between tumor response and survival following radiotherapy for carcinoma of the bronchus
4. Local control in medically inoperable lung cancer: An analysis of its importance in outcome and factors determining the probability of tumor eradication
5. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with ≥69.6 Gy in favorable patients with radiation therapy oncology group stage III non-small cell lung carcinoma - Report of Radiation Therapy Oncology Group 83-11
6. Tolerance of normal tissue to therapeutic irradiation
7. Calculation of complication probability factors for non-uniform normal tissue irradiation: The effective volume method
8. Optimization of radiation therapy: III. A method of assessing complication probabilities from dose-volume histograms
9. Induction of acute phase gene expression by brain irradiation
10. A perpetual cascade of cytokines post irradiation leads to pulmonary fibrosis
11. Cellular basis of radiation-induced fibrosis
12. Molecular biology mechanisms in the radiation induction of pulmonary injury syndromes: Interrelationship between the alveolar macrophage and the septal fibroblast
13. Early alteration in extracellular matrix and transforming growth factor β gene expression in mouse lung indicative of late radiation fibrosis
14. Ionizing radiation induces rapid tyrosine phosphorylation of p 34cdc2
15. Activation of the c-Ab tyrosine kinase in the stress response to DNA-damaging agents
16. Nuclear signaling induced by ionizing radiation involves colocalization of the activated p56/p53lyn tyrosine kinase with p34cdc2
17. The stress response to ionizing radiation involves c-Ab-dependent phosphorylation of SHPTP 1
18. Mechanisms of X-ray-mediated protooncogene c-jun expression in radiation-induced human sarcoma cell lines
19. Ketoconazole attenuates radiation-induction of tumor necrosis factor
20. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells
21. Ionizing radiation induces expression and binding activity of the nuclear factor kappa B
22. Differences in correlation of mRNA gene expression in mice sensitive and resistant to radiation-induced pulmonary fibrosis
23. Intercellular adhesion molecule 1 knockout abrogates radiation induced pulmonary inflammation
24. Ionizing radiation mediates expression of cell adhesion molecules in distinct histological patterns within the lung
25. Fibroblast radiosensitivity in vitro and lung fibrosis in vivo: Comparison between a fibrosis-prone and fibrosis-resistant mouse strain
26. Immunohistochemical localization of transforming growth factor beta and tumor necrosis factor alpha in the lungs of fibrosis-prone and & "non-fibrosing" mice during the latent period and early phase after irradiation
27. Magnesium superoxide dismutase (MnSOD) plasmid/liposome pulmonary radioprotective gene therapy: Modulation of irradiation-induced mRNA for IL-1, TNF-α, and TGF-β correlates with delay of organizing alveolitis/fibrosis
28. The physical parameters and molecular events associated with radiation-induced lung toxicity
29. Plasma transforming growth factor β1 as a predictor of radiation pneumonitis
30. Circulating IL-6 as a predictor of radiation pneumonitis
31. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biological parameters V30 and transforming growth factor β
32. The effect of patient-specific factors on radiation-induced regional lung injury
33. Transforming growth factors: Isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction
34. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: Unusual toxicity and promising early results
35. Clinical trials in cancer: Design and analysis of clinical trials
36. Nonparametric estimations from incomplete observations
37. Cancer statistics
38. A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III NSCLC
39. Significant effect of adjuvant chemotherapy on survival and locally advanced non-small cell lung cancer
40. Effects of concomitant cisplatin and radiotherapy in inoperable nonsmall cell lung cancer
41. A meta-analysis using updated data on individual patients from 52 randomized clinical trials
42. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIA and IIIB non-small cell lung cancer
43. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer: A meta-analysis
44. Effective chemotherapy on locally advanced non-small cell lung carcinoma: A randomized study of 353 patients
45. Hyperfractionated radiotherapy of human tumors: Overview of the randomized clinical trials
46. Normal tissue injury after cancer therapy is a local manifestation of a systemic condition
47. Transforming growth factor-β1 expression in irradiated liver
48. Transforming growth factor beta activation in irradiated murine mammary gland
49. How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues
50. Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin
51. Redox-mediated activation of latent transforming growth factor-β1
52. TGF-β1 and radiation fibrosis: A master switch and a specific target?
53. TGFβ1 is an important contributing factor in the development of radiation induced fibrosis
54. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer
55. Changes in plasma TGF-β levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis
56. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis
57. Plasma TGF-β levels during radiotherapy with or without carboplatin predicts pneumonitis in stage III non-small cell lung cancer
58. TGFβ, radiation-induced pulmonary injury and lung cancer
59. Results of radical radiation therapy in clinical stage 1, technically operable non-small cell lung cancer
60. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer: A randomized, phase III trial
61. Radiation pneumonitis following combined modality therapy for lung cancer: Analysis of prognostic factors
62. How much could the radiotherapy dose be altered for individual patients based on a predictive assay of normal tissue radiosensitivity?
63. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: Update of a phase I trial
64. Alterations in pulmonary mRNA encoding procollagens, fibronectin, and transforming growth factor beta precede bleomycin-induced pulmonary fibrosis
65. Early increases in pulmonary mRNA encoding procollagens and transforming growth factor beta in mice sensitive to cyclophosphamide-induced pulmonary fibrosis
66. Transforming growth factors beta-1 and alpha in chronic liver disease: Effects of interferon alpha therapy
67. Transforming growth factor beta-1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis
68. Elevated plasma TGFβ1 levels in breast cancer patients decrease following removal of the tumor
69. Plasma transforming growth factor β1 reflects disease status in patients with lung cancer after radiotherapy: A possible tumor marker
70. Elevated plasma levels of TGFβ1 in patients with invasive prostate cancer
71. Elevated levels of plasma transforming growth factor-β in patients with hepatocellular carcinoma
72. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma: Comparison with chronic liver diseases
73. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury
74. Plasma transforming growth factor-betal level before radiotherapy correlates with long term outcome of patients with lung carcinoma
75. Counterpoint: Better radiation treatment of non-small cell lung cancer using new techniques without elective nodal irradiation